CANC vs IBB

Key Takeaways

• Tema Oncology ETF (CANC) is an actively managed thematic fund concentrating on companies deriving significant revenue from oncology, while iShares Biotechnology ETF (IBB) passively tracks a broad Nasdaq Biotechnology Index.
• CANC holds approximately 58–60 securities with a net expense ratio of 0.75%, compared to IBB’s roughly 248 holdings and 0.35% expense ratio.
• CANC provides targeted exposure to cancer therapeutics and care, whereas IBB offers diversified exposure across the broader biotechnology sector within healthcare.
• Both ETFs operate entirely within the healthcare sector, exposing investors to similar macro drivers including regulatory approvals, clinical trial outcomes, and interest-rate sensitivity.
• CANC’s active strategy and higher cost reflect its narrower thematic mandate, while IBB’s passive structure emphasizes lower costs and broader diversification.
• Relative positioning favors IBB for cost efficiency and diversification, whereas CANC suits investors seeking concentrated oncology-specific opportunities.

Introduction

Investors evaluating biotechnology and healthcare exposure often compare specialized thematic vehicles with established sector benchmarks. Tema Oncology ETF (CANC) and iShares Biotechnology ETF (IBB) both target segments of the healthcare industry but employ fundamentally different approaches. CANC pursues an active, oncology-focused strategy, while IBB delivers passive, broad-based biotechnology exposure. These differences make the pair useful for understanding trade-offs between thematic concentration and sector-wide diversification in the current market environment.

Tema Oncology ETF (CANC) Overview

Tema Oncology ETF (CANC) is an actively managed exchange-traded fund launched in August 2023. The fund seeks long-term growth by investing at least 80% of its net assets in publicly listed companies that derive at least 50% of revenues from oncology-related activities. It maintains approximately 58–60 holdings and applies a bottom-up selection process. Top holdings typically include Revolution Medicines Inc., Eli Lilly & Co., Cogent Biosciences Inc., Novartis AG, and Roche Holding AG. The net expense ratio stands at 0.75%. As an actively managed thematic product, CANC features concentrated exposure to cancer therapeutics and care, distinguishing it from broader passive benchmarks.

iShares Biotechnology ETF (IBB) Overview

iShares Biotechnology ETF (IBB) is a passively managed fund that seeks to track the investment results of the Nasdaq Biotechnology Index, which comprises U.S.-listed equities in the biotechnology sector. The ETF holds approximately 248 securities and maintains an expense ratio of 0.35%. Top holdings generally feature large-capitalization names such as Amgen Inc., Gilead Sciences Inc., and Regeneron Pharmaceuticals Inc. Sector allocation is essentially 100% healthcare, with the vast majority in biotechnology and life sciences tools and services. IBB offers broad diversification within the biotechnology industry through a rules-based index methodology with periodic rebalancing.

Industry and Thematic Backdrop

The biotechnology and oncology segments operate within the larger healthcare sector, influenced by clinical trial results, U.S. Food and Drug Administration (FDA) approvals, patent expirations, and reimbursement policies. Macroeconomic factors including interest-rate expectations and capital availability affect growth-oriented healthcare companies. Recent market cycles have highlighted both innovation-driven opportunities in targeted cancer therapies and broader sector volatility tied to regulatory and competitive pressures. Capital continues to flow toward companies demonstrating strong pipelines in precision oncology and related modalities.

Performance and Positioning Comparison

Over recent weeks and months, both ETFs have reflected healthcare sector rotation driven by earnings cycles of major holdings and evolving interest-rate expectations. CANC’s concentrated oncology focus has produced differentiated performance relative to the broader biotechnology market tracked by IBB. IBB’s larger number of holdings and lower expense ratio support more stable relative positioning across market cycles, while CANC exhibits higher potential volatility consistent with its thematic concentration. Sector momentum in oncology versus general biotech remains a key differentiator in relative returns.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to discover additional investment opportunities aligned with your strategy.

Tickeron AI Verdict

Based on observable structural characteristics, iShares Biotechnology ETF (IBB) currently presents a more balanced profile for broad biotechnology exposure due to its lower expense ratio, greater diversification across holdings, and established passive methodology. Tema Oncology ETF (CANC) offers differentiated oncology-specific exposure that may appeal to investors with higher risk tolerance seeking thematic concentration. The AI assessment favors IBB for cost efficiency and diversification while recognizing CANC’s potential role in targeted portfolios.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations